The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback